Scalper1 News
Specialty drugmaker and IBD 50 stock Jazz Pharmaceuticals was up 8% in early afternoon trading on the stock market today after the company late Tuesday beat Q2 estimates and raised its outlook. Jazz Pharmaceuticals (JAZZ) was the last of a group of top drug stocks that reported Q2 earnings on Tuesday, and it wound up with the biggest stock bump of all of them. Leerink analyst Jason Gerberry raised his price target to 181 from 177, noting that the Scalper1 News
Scalper1 News